Pituitary adenomas can appear as hypermetabolic lesions in 18F-FDG PET imaging

Journal of Neuroimaging

Volumn 20, Issue 4, 2010, Pages 393-396

  Ryu, Stephen I ^a,b   Tafti, Bashir A ^a,b   Skirboll, Stephen L ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Hypermetabolic; Melanoma; Pituitary adenoma; Positron emission tomography (PET)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN REGION; CANCER STAGING; CASE REPORT; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; HEMISPHERE; HUMAN; HYPOPHYSIS ADENOMA; LYMPH NODE METASTASIS; MALE; MELANOMA; NECK DISSECTION; NEOCORTEX; NEUROIMAGING; NOCTURNAL SEIZURE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SURGICAL APPROACH;

ADENOMA; AGED; BRAIN DISEASES, METABOLIC; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 78349293832     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2008.00347.x     Document Type: Article

References (12)

1. Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005;33(3):145-155; quiz 162-3.
2. Komori T, Martin WH, Graber AL. Serendipitous detection of Cushing's disease by FDG positron emission tomography and a review of the literature. Clin Nucl Med 2002;27(3):176-178.
3. Francavilla TL, Miletich RS, DeMichele D. Positron emission tomography of pituitary macroadenomas: hormone production and effects of therapies. Neurosurgery 1991;28(6):826-833.
4. Bergstrom M, Muhr C, Lundberg PO. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 1991;32(4):610-615.
5. Boni R, Boni RA, Steinert H. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995;122(4):556-562.
6. Steinert HC, Huch Boni RA, Buck A. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;195(3):705-709.
7. Swetter SM, Carroll LA, Johnson DL. Poistron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Annals of Surg Onc 2002;9(7):646-653.
8. Rinne D, Baum RP, Hor G. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998;82(9):1664-1671.
9. Eigtved A, Andersson AP, Dahlstrom K. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27(1):70-75.
10. Prichard RS, Hill AD, Skehan SJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002;89(4):389-396.
11. De Souza B, Brunetti A, Fulham MJ. Pituitary microadenomas: a PET study. Radiology 1990;177(1):39-44.
12. Campeau RJ, David O, Dowling AM. Pituitary adenoma detected on FDG positron emission tomography in a patient with mucosa-associated lymphoid tissue lymphoma. Clin Nucl Med 2003;28(4):296-298.